Open an account

Arcturus Therapeutics Holdings

ARCT · NASDAQ

$10.98+$0.56 (+5.37%)TodayMarket closed ·
Prev close $10.42

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 106 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Employees
106
Headquarters
San Diego, California
Listed
May 22, 2013
Sector
Health Care
Industry
Biotechnology
Website
arcturusrx.com

ARCT key statistics

Market cap
312.09M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
753.06K
Volume
869.48K
Open price
$10.42
High today
$11.52
Low today
$10.30
52 Week high
$24.17
52 Week low
$5.50

Arcturus Therapeutics Holdings (ARCT) at a glance

As of Oct 20, 2026, Arcturus Therapeutics Holdings (ARCT) shares are priced at $10.98, giving the company a market cap of 312.09M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.30 and $11.52. The current price is 6.7% above the day's low and 4.7% below its high.

Volume so far is 869.48K shares, in line with the average of 753.06K shares a day.

Over the past year Arcturus Therapeutics Holdings has ranged from $5.50 to $24.17, and now sits 29% of the way up that range.

Arcturus Therapeutics Holdings met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.84 per share against an estimate of -$1.02.

The average analyst price target is $23.66, 115.5% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 10 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 12 analystsAvg $23.66
Low
$9.09
Now
$10.98
High
$43.05

ARCT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 46.2% on average.

  1. Q3 FY24: reported -$0.26 per share against an estimate of -$1.24
  2. Q4 FY24: reported -$1.11 per share against an estimate of -$0.56
  3. Q1 FY25: reported -$0.52 per share against an estimate of -$1.36
  4. Q2 FY25: reported -$0.34 per share against an estimate of -$0.9096
  5. Q3 FY25: reported -$0.49 per share against an estimate of -$0.8397
  6. Q4 FY25: reported -$1.03 per share against an estimate of -$0.7274
  7. Q1 FY26: reported -$0.95 per share against an estimate of -$1.11
  8. Q2 FY26: reported -$0.84 per share against an estimate of -$1.02

ARCT news

  • Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • Vandana Singh

    Why Is Arcturus Therapeutics Stock Gaining Thursday?

  • Press releaseBusiness Wire

    Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

  • Press releaseBusiness Wire

    Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

  • Press releaseBusiness Wire

    Arcturus Therapeutics to Participate in Upcoming Investor Conferences

  • Radhika Anilkumar Nadig

    Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Arcturus Therapeutics Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.